Cited by 653Cancer-related Molecular PathwaysUbiquitin and proteasome pathwaysHeat shock proteins research

The DOI matches its Crossref record; 134 of the 144 references it cites were found in a registry or an index.

MDM2 — master regulator of the p53 tumor suppressor protein

Momand, Jamil, Wu, Hsiao-Huei, Dasgupta, Gargi·2000·Gene

Open this paper in CoChat — free account

Abstract

MDM2 is an oncogene that mainly functions to modulate p53 tumor suppressor activity. In normal cells the MDM2 protein binds to the p53 protein and maintains p53 at low levels by increasing its susceptibility to proteolysis by the 26S proteosome. Immediately after the application of cellular stress, the ability of MDM2 to bind to p53 is blocked or altered in a fashion that prevents MDM2-mediated degradation. As a result, p53 levels rise, causing cell cycle arrest or apoptosis. In this review, we present evidence for the existence of three highly conserved regions (CRs) shared by MDM2 proteins and MDMX proteins of different species. These highly conserved regions encompass residues 42-94 (CR1), 301-329 (CR2), and 444-483 (CR3) on human MDM2. These three domains are respectively important for binding p53, for binding the retinoblastoma protein, and for transferring ubiquitin to p53. This review discusses the major milestones uncovered in MDM2 research during the past 12 years and potential uses of this knowledge in the fight against cancer.

Integrity signals

Registry

Crossref · 10.1016/s0378-1119(99)00487-4

Cites

134 of 134 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

THE UBIQUITIN SYSTEM
Hershko, A., & Ciechanover, A. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.425 · Cited by 8,840
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312
The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Self-citation

Show all 144 references

Sorted by citations

Items 601–653 of 653

Sensitization of Cancer Cells via Non-Viral Delivery of Apoptosis Inducing Proteins Using a Cationic Bolaamphiphile
Narayanan, K., Khan, M., Gopalan, B., Antony, J., Das, T., Yang, Y. Y., & Wan, A. C. A. (2018) · Biotechnology Journal · doi:10.1002/biot.201800020
Development of novel PROTAC Small-Molecule Degraders of MDM2 Protein and Peptidomimetic Inhibitors Targeting WDR5-MLL1 Protein-Protein Interaction
Li, Y. (2018) · Deep Blue (University of Michigan)
Surface plasmon resonance and cytotoxicity assays of drug efficacies predicted computationally to inhibit p53/MDM2 interaction
Wang, X., Magdziarz, P., Enriquez, E., Zhao, W., Quan, C., Darabedian, N., Momand, J. A., & Zhou, F. (2019) · Analytical Biochemistry · doi:10.1016/j.ab.2019.01.012
Self-citation
The role of p53 family members in myogenic differentiation and rhabdomyosarcoma development
Çam, H. (2006) · Online Publication Service of Würzburg University (Würzburg University)
Peer Review #1 of "Master regulator genes and their impact on major diseases (v0.1)"
(2020) · PeerJ · doi:10.7287/peerj.9952v0.1/reviews/1
Peer Review #3 of "Master regulator genes and their impact on major diseases (v0.1)"
(2020) · PeerJ · doi:10.7287/peerj.9952v0.1/reviews/3
Identification of fitness genes and genotype-specific vulnerabilities using functional genetic screens in human cancer cells
Chandrashekhar, M. (2018) · TSpace (University of Toronto)
Discovery of Novel Inhibitors Targeting HDM2: Virtual Screening, Molecular Dynamics Simulation and Binding affinity predicationPreprint
Cao, F., Chen, L., Xiong, F., Liu, X., & Zhang, L. (2021) · Research Square · doi:10.21203/rs.3.rs-905935/v1
MDM 2
Lozano, G. (2002) · Wiley Encyclopedia of Molecular Medicine · doi:10.1002/0471203076.emm0239
Discovery of Novel Inhibitors Targeting HDM2: Virtual Screening, Molecular Dynamics Simulation, Binding affinity predication and Cell AssayPreprint
Cao, F., Liang, C., Xiong, F., Li, H., Liu, X., & Zhang, L. (2022) · Research Square · doi:10.21203/rs.3.rs-1410429/v1
Toxicogenomics for the prediction of carcinogenicity of xenobiotic substances
Srivastava, A. K., Kumar, D., Singh, D. R., & Singh, R. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90560-2.00005-4
Peer Review #2 of "Master regulator genes and their impact on major diseases (v0.1)"
(2020) · PeerJ · doi:10.7287/peerj.9952v0.1/reviews/2
Protein-Protein Interactions (PPIs) as an Alternative to Targeting the ATP Binding Site of Kinase
Sarvagalla, S., & Coumar, M. S. (2016) · IGI Global eBooks · doi:10.4018/978-1-5225-1762-7.ch043
NF90–NF45 is essential for β cell compensation under obesity-inducing metabolic stress through suppression of p53 signaling pathway
Lai, S., Higuchi, T., Tsuda, M., Sugiyama, Y., Morisawa, K., Taniguchi, T., & Sakamoto, S. (2022) · Scientific Reports · doi:10.1038/s41598-022-12600-y
Activating the p53 anti-cancer pathway by targeting the MDM2/MDMX dimer interface with short peptide segments: a computational peptide design experiment
ElSawy, K. M., Alminderej, F. M., Verma, C. S., & Caves, L. S. D. (2022) · Molecular Systems Design & Engineering · doi:10.1039/d2me00042c
A rare case of well-differentiated liposarcoma with CDK4 amplification but without MDM2 amplificationPreprint
Xu, D., Wang, Z., Cao, H., & Qiu, X. (2022) · Research Square · doi:10.21203/rs.3.rs-1794905/v1
Pinning Control to Regulate Cellular Response in Cancer for the p53-Mdm2 Genetic Regulatory Network
Suárez, O. J., Vega, C. J., Sanchez, E. N., Chen, G., Santiago, A. E. G., Rodríguez-Jorge, O., Alanís, A. Y., & Hernandez-Vargas, E. A. (2022) · Emergence, complexity and computation · doi:10.1007/978-3-031-04379-6_6
A Case of Dedifferentiated Liposarcoma of the Chest Wall
Numata, A., Ochi, T., Yoshida, A., Hayashi, N., Nozaki, F., Tsunoda, H. S., & Yamauchi, H. (2022) · Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) · doi:10.3919/jjsa.83.1417
Data from Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma
Maerken, T. V., Speleman, F., Vermeulen, J., Lambertz, I., Clercq, S. D., Smet, E. D., Yigit, N., Coppens, V., Philippé, J., Paepe, A. D., et al. (2023) · doi:10.1158/0008-5472.c.6494438
Data from Small-Molecule MDM2 Antagonists as a New Therapy Concept for Neuroblastoma
Maerken, T. V., Speleman, F., Vermeulen, J., Lambertz, I., Clercq, S. D., Smet, E. D., Yigit, N., Coppens, V., Philippé, J., Paepe, A. D., et al. (2023) · doi:10.1158/0008-5472.c.6494438.v1
Disruption of p54nrb's gene regulatory function by caspase-2 exhibits a multifaceted role in tumor cell death susceptibility
Eichler, M. (2023) · doi:10.21248/gups.74656
Estudos in silico, síntese e avaliação de atividade leishmanicida e tripanocida in vitro de novos potenciais inibidores de proteassoma
Gomes, S. Q. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.59.2023.tde-11082023-100051
The p53 tumor suppressor protein activates transcription of DUSP13 isoform from the alternative promoter in intron 3Preprint
Krześniak, M., Łasut-Szyszka, B., Będzińska, A., Gdowicz‐Kłosok, A., & Rusin, M. (2023) · Preprints.org · doi:10.20944/preprints202309.1653.v1
The p53 tumor suppressor protein activates transcription of DUSP13 isoform from the alternative promoter in intronPreprint
Krześniak, M., Łasut-Szyszka, B., Będzińska, A., Gdowicz‐Kłosok, A., & Rusin, M. (2024) · Preprints.org · doi:10.20944/preprints202309.1653.v2
External noise-induced stochastic resonance and stochastic transitions in p53-Mdm2 regulatory network
Jiang, C., Dai, C., & Wang, K. (2024) · International Journal of Biomathematics · doi:10.1142/s1793524524501158
Stability Analysis of Dynamic P53-MDM2 with Time Delay
Luvsantseren, P., Lochin, K., & Luvsan‐Ish, A. (2024) · International Conference on Medical and Health Informatics (ICMHI) · doi:10.1145/3673971.3673981
Targeting the p53/MDM2 Pathway for Cancer Therapy
Klein, C., & Vassilev, L. T. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-274-8_2
Modeling of Cancer Signaling Pathways
Karabekmez, R. (2013) · UWSpace (University of Waterloo)
Modélisation génétique de l'oncogenèse mésothéliale induite par les fibres minérales
Boulangé-Lecomte, C. (2004) · OpenGrey (Institut de l'Information Scientifique et Technique)
TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a comprehensive overview of targeted approaches
Deshpande, S., Li, W. F., Song, J., Forsberg, M., Cerchione, C., Martinelli, G., & Konopleva, M. Y. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1735418
Etude de la réparation des cassures double-brin de l'ADN dans les cellules souches du muscle squelettique et leurs progéniteurs
Ferdousi, L. V. (2014) · theses.fr (ABES) · doi:10.70675/9d73199ez7949z4602zadcfz6763e4bdd1b0
Développement de nouveaux tests fonctionnels d'aide à l'interpretation des variants de signification biologique inconnue dans le cadre de prédispositions génétiques au cancer.
Raad, S. (2018) · theses.fr (ABES) · doi:10.70675/55ae189az669fz4544z90baz1c170bc934c6
Conception, synthèse et purification d’analogues de molécules de venin animal à action inhibitrice des cellules
Moslah, W. (2022) · doi:10.70675/069afadezcd0az4404zbb42z0159cebb1df6
De novo design and evaluation of dual inhibitory peptide binders targeting MDMX-p53 and MDM2-p53 interactions
Durojaye, O. A., Bellah, S. F., Uzoeto, H. O., Ezechukwu, S. P., Arazu, A. V., Ajima, J. N., Ngwu, A. N., & Cosmas, S. (2026) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-026-00765-8
Phase separation of tumor suppressor p53 and its family proteins
Paul, A., & Maji, S. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-99507-8.00084-6
Navigating the p53‐MDM2 Landscape: Molecular Insights and Therapeutic Strategies
Mansour, M. A., Hassan, G. S., & Abouzid, K. A. M. (2026) · Archiv der Pharmazie · doi:10.1002/ardp.70264
Optimization of osteosarcoma sample processing for epigenetic analysis: A comparative evaluation of formalin-fixed, paraffin-embedded samples with and without decalcification versus fresh tissue
González-López, J., González‐Rojo, P., Berenguer-Rubio, A., Casaní-Galdón, S., García, D., Valera, M. S., Vidal, A., Huart, M. C., Rangel, A., de la Calva, C., et al. (2026) · Revista Española de Patología · doi:10.1016/j.patol.2026.100881
BindingDB Entry 50020914: Discovery of ganoderic acid A (GAA) PROTACs as MDM2 protein degraders for the treatment of breast cancer.
BindingDB (2025) · UC San Diego · doi:10.7270/q2j67nhw
BindingDB Entry 50045000: Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles.
BindingDB (2016) · UC San Diego · doi:10.7270/q2hh6mqk
BindingDB Entry 50044538: Pivotal Role of an Aliphatic Side Chain in the Development of an HDM2 Inhibitor.
BindingDB (2015) · UC San Diego · doi:10.7270/q26h4jzb
BindingDB Entry 50010808: Medicinal Chemistry of Inhibiting RING-Type E3 Ubiquitin Ligases.
BindingDB (2021) · UC San Diego · doi:10.7270/q2qn6bbk
BindingDB Entry 3460: N-acylpolyamine inhibitors of HDM2 and HDMX binding to p53.
BindingDB (2009) · UC San Diego · doi:10.7270/q2057d90
BindingDB Entry 50019259: DNA-Encoded Macrocyclic Peptide Libraries Enable the Discovery of a Neutral MDM2-p53 Inhibitor.
BindingDB (2024) · UC San Diego · doi:10.7270/q2cz3ch3
BindingDB Entry 50045594: Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
BindingDB (2016) · UC San Diego · doi:10.7270/q21g0nz5
BindingDB Entry 50001897: Small Molecules Simultaneously Inhibiting p53-Murine Double Minute 2 (MDM2) Interaction and Histone Deacetylases (HDACs): Discovery of Novel Multitargeting Antitumor Agents.
BindingDB (2020) · UC San Diego · doi:10.7270/q2r213z9
BindingDB Entry 50001621: Simultaneous Targeting of RGD-Integrins and Dual Murine Double Minute Proteins in Glioblastoma Multiforme.
BindingDB (2020) · UC San Diego · doi:10.7270/q22j6fcb
BindingDB Entry 3310: Discovery of a nanomolar inhibitor of the human murine double minute 2 (MDM2)-p53 interaction through an integrated, virtual database screening strategy.
BindingDB (2009) · UC San Diego · doi:10.7270/q20p0xcm
BindingDB Entry 50049265: Discovery of 4-((3'R,4'S,5'R)-6¿-Chloro-4'-(3-chloro-2-fluorophenyl)-1'-ethyl-2¿-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3¿-indoline]-5'-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Deve
BindingDB (2019) · UC San Diego · doi:10.7270/q25q4zcf
BindingDB Entry 50006378: 2,30-Bis(10H-indole) heterocycles: New p53/MDM2/MDMX antagonists.
BindingDB (2020) · UC San Diego · doi:10.7270/q2wm1hf9
BindingDB Entry 3311: Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction.
BindingDB (2009) · UC San Diego · doi:10.7270/q2vx0dvv
BindingDB Entry 50043814: Substituted piperidines as HDM2 inhibitors.
BindingDB (2014) · UC San Diego · doi:10.7270/q2765gt9
Charakterisierung der Wechselwirkungen zwischen dem Notch-Signalweg und intrinsischen und extrinsischen Signalen in hämatopoetischen Zellen
Henning, K. (2007) · MACAU: Open Access Repository of Kiel University (University Library Kiel)
Untitled work
(2000) · doi:10.1002/1097-0215(20001015)88:2

Authors: Momand, J., Wu, H.-H., & Dasgupta, G.
Affiliations: California State University Los Angeles (US)
Corresponding author: Momand, Jamil
ORCID: Momand, Jamil
Wu, Hsiao-Huei
Venue: Gene
Publisher: Elsevier BV
Published: 2000-01
Volume: 242
Issue: 1-2
Pages: 15-29
ISSN: 0378-1119 (ISSN-L)
DOI: 10.1016/s0378-1119(99)00487-4
OpenAlex: W1973821009
Cited by: 641
References: 144
Citations by year: 2026: 6 · 2025: 11 · 2024: 17 · 2023: 19 · 2022: 24 · 2021: 10 · 2020: 17 · 2019: 16 · 2018: 22 · 2017: 14 · 2016: 17 · 2015: 31 · 2014: 21 · 2013: 21 · 2012: 24
FWCI: 4.03
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Gene (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Keywords: MDM2, p53, tumor suppressor regulation, MDMX, conserved domains, p53 ubiquitination, proteasomal degradation, cell cycle arrest, apoptosis, oncogenes, cancer therapy
MeSH terms: Amino Acid Sequence, Animals, Gene Expression Regulation, Humans, Models, Biological, Molecular Sequence Data, Nuclear Proteins, Proto-Oncogene Proteins, Genes, Tumor Suppressor, Tumor Suppressor Protein p53, Sequence Homology, Amino Acid, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MDM2 — master regulator of the p53 tumor suppressor protein

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks